These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 18348679)

  • 61. Management of Parkinson's disease a review of current and new therapies.
    Mendis T; Suchowersky O; Lang A; Gauthier S
    Can J Neurol Sci; 1999 May; 26(2):89-103. PubMed ID: 10352867
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of advanced Parkinson's disease.
    Giugni JC; Okun MS
    Curr Opin Neurol; 2014 Aug; 27(4):450-60. PubMed ID: 24978634
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Milestones in Parkinson's disease therapeutics.
    Rascol O; Lozano A; Stern M; Poewe W
    Mov Disord; 2011 May; 26(6):1072-82. PubMed ID: 21626552
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease.
    van Wamelen DJ; Leta V; Chaudhuri KR; Jenner P
    Curr Neuropharmacol; 2024; 22(10):1606-1620. PubMed ID: 37526188
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.
    Dézsi L; Vécsei L
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):409-24. PubMed ID: 24437461
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New small molecules for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Etiopathogenesis and treatment of Parkinson's disease.
    Gallagher DA; Schapira AH
    Curr Top Med Chem; 2009; 9(10):860-8. PubMed ID: 19754402
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rational drug discovery design approaches for treating Parkinson's disease.
    Van der Schyf CJ
    Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 72. New directions in the drug treatment of Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The safety of dopamine agonists in the treatment of Parkinson's disease.
    Bonuccelli U; Ceravolo R
    Expert Opin Drug Saf; 2008 Mar; 7(2):111-27. PubMed ID: 18324875
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Future drug targets for Parkinson's disease].
    Hirsch EC
    Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Modern therapy of Parkinson's disease.
    Ransmayr G; Künig G; Gerstenbrand F
    J Neural Transm Suppl; 1992; 38():129-40. PubMed ID: 1491245
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2017 Oct; 18(14):1457-1465. PubMed ID: 28847181
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mechanism of action of dopaminergic agents in Parkinson's disease.
    Koller WC; Rueda MG
    Neurology; 1998 Jun; 50(6 Suppl 6):S11-4; discussion S44-8. PubMed ID: 9633680
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Parkinson's disease. Second of two parts.
    Lang AE; Lozano AM
    N Engl J Med; 1998 Oct; 339(16):1130-43. PubMed ID: 9770561
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.